Categories
Change Password!
Reset Password!
In patients with psoriasis, IL-23 inhibitors are more effective than IL-17 inhibitors in reducing the risk of psoriatic arthritis, particularly among middle-aged individuals, females, and White patients.
A new study suggests that interleukin-23 inhibitors (IL23i) may offer better protection against psoriatic arthritis in patients with psoriasis when compared to interleukin-17 inhibitors (IL17i). Psoriatic arthritis is a commonly encountered comorbidity in psoriasis patients, causing an increased disease burden. Biologic therapies targeting the IL-23 and IL-17 pathways have been extensively utilized for psoriasis, but their role in psoriatic arthritis prevention remains unclear.
Therefore, this retrospective study analyzed real-world data from 53 healthcare organizations to compare the effectiveness of IL-targeting agents in curtailing psoriatic arthritis risk. Researchers conducted a cohort study of 4,580 adults with psoriasis who received either IL23i (2,273 patients) or IL17i (2,307 patients). Cox regression analysis evaluated the risk of psoriatic arthritis incidence, presenting hazard ratios (HRs) with 95% confidence intervals (CIs).
Subgroup analyses were conducted by age, sex, and ethnicity, while sensitivity analyses incorporated comparisons with tumor necrosis factor inhibitors (TNFi) to validate robustness. Patients treated with IL23i exhibited a lower risk of developing psoriatic arthritis than those on IL17i. The effect was most pronounced in individuals aged 41-65 years and in women. Ethnicity-based analysis showed a significant risk reduction in White patients but no clear benefit in Black or African American patients (Table 1).
Sensitivity analyses comparing IL-23i and TNFi reinforced the robustness of the findings. Thus, IL23i may be a more suitable biologic therapy for psoriasis patients at high risk of developing psoriatic arthritis, particularly for middle-aged adults, females, and White patients. The findings emphasize the significance of tailoring therapeutic strategies to account for patient-specific factors, such as age, sex, and ethnicity, when choosing biologic therapy.
BioDrugs
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network
Sebastian Yu et al.
Comments (0)